KATHRYN E FALBERG
CIK 1206977 · EVP and CFO · last filed 2026-05-26
KATHRYN E FALBERG is an EVP and CFO who has filed 121 SEC Form 4 insider transactions across 15 companies since 2007. The most recent filing, for NUVB, was dated May 26, 2026. Across all open-market trades the lifetime net is −$70.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $35.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$34.97M
15
121
-$70.27M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVB | Director | — | $4.92 | — | $0 | 1 | 2026-05-26 |
| TTD | Director | 212 | $19.28 | $4.1K | -$73.56M | 24 | 2026-03-25 |
| RCUS | Director | 170,706 | $23.80 | $4.06M | $1.55M | 12 | 2025-06-12 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 75,041 | $0.01 | $383 | $483.8K | 8 | 2025-05-23 |
| Tricida, Inc. (TCDA) Delisted | Director | 59,163 | $0.11 | $6.4K | $600.0K | 5 | 2022-06-16 |
| URGN | Director | — | $29.72 | — | $0 | 3 | 2021-06-09 |
| COLL | Director | 0 | $34.64 | $0 | $960.0K | 7 | 2020-10-14 |
| BMRN | Director | 2,640 | $55.95 | $147.7K | $0 | 2 | 2016-09-01 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 82,742 | — | — | $2.94M | 7 | 2016-06-23 |
| LIFE | Director | — | $15.61 | — | $0 | 3 | 2016-05-26 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Director | 358,253 | — | — | $942.1K | 12 | 2016-05-06 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 94,894 | — | — | $400.0K | 1 | 2015-08-11 |
| JAZZ | EVP and CFO | 133,387 | $230.56 | $30.75M | -$4.52M | 27 | 2014-03-06 |
| QLTI | Director | — | $26.82 | — | $0 | 3 | 2011-05-27 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | CFO and COO | 12,800 | $28.80 | $368.6K | -$75.9K | 3 | 2009-06-26 |
Recent Filings
121 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-26 | NUVB | Grant (A) | — | $0 | EDGAR |
| 2026-03-25 | TTD | Disp (D) | −1,946 | -$42.6K | EDGAR |
| 2026-03-09 | TTD | Sell (S) | −152,828 | -$4.66M | EDGAR |
| 2025-06-12 | RCUS | Grant (A) | +13,300 | $0 | EDGAR |
| 2025-05-29 | TTD | Grant (A) | +7,774 | $170.0K | EDGAR |
| 2025-05-23 | Nuvation Bio Inc. (NUVB.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-04-17 | TTD | Grant (A) | +90 | $5.7K | EDGAR |
| 2024-09-05 | Nuvation Bio Inc. (NUVB.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-15 | TTD | Sell (S) | −150,000 | -$14.73M | EDGAR |
| 2024-06-07 | RCUS | Grant (A) | +8,400 | $0 | EDGAR |